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Background: Hypoxia within solid tumors confers radiation resistance and a poorer prognosis. 124I-iodoazomycin
galactopyranoside (124I-IAZGP) has shown promise as a hypoxia radiotracer in animal models. We performed a
clinical study to evaluate the safety, biodistribution, and imaging characteristics of 124I-IAZGP in patients with
advanced colorectal cancer and head and neck cancer using serial positron emission tomography (PET) imaging.
Methods: Ten patients underwent serial whole-torso (head/neck to pelvis) PET imaging together with multiple
whole-body counts and blood sampling. These data were used to generate absorbed dose estimates to normal
tissues for 124I-IAZGP. Tumors were scored as either positive or negative for 124I-IAZGP uptake.
Results: There were no clinical toxicities or adverse effects associated with 124I-IAZGP administration. Clearance
from the whole body and blood was rapid, primarily via the urinary tract, with no focal uptake in any parenchymal
organ. The tissues receiving the highest absorbed doses were the mucosal walls of the urinary bladder and the
intestinal tract, in particular the lower large intestine. All 124I-IAZGP PET scans were interpreted as negative for
tumor uptake.
Conclusions: It is safe to administer 124I-IAZGP to human subjects. However, there was insufficient tumor uptake to
support a clinical role for 124I-IAZGP PET in colorectal cancer and head and neck cancer patients.
Trial registration: ClinicalTrials.gov NCT00588276
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Colorectal cancerBackground
There is substantial evidence that tumor hypoxia is an
important indicator of clinical prognosis for human
cancer. The hypoxic tumor phenotype is complex; its
various aspects include reduced sensitivity to low LET
radiation, differential patterns of gene expression, en-
hanced angiogenesis, and an increased propensity to meta-
static dissemination [1-8]. Although a full understanding* Correspondence: odonoghj@mskcc.org
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relatively simple polarographic probe measurements in
accessible tumors typically show a difference in survival
between patients with hypoxic tumors and those with
non-hypoxic tumors [9-11]. It follows that a non-invasive
imaging method, even if it could provide only the same
information as polarographic probes, could potentially
help predict tumor behavior and enable individualized
courses of treatment to be designed on a rational basis.
Positron emission tomography (PET) using hypoxia-
selective radiotracers has been proposed as a non-invasive
method of visualizing hypoxia within solid tumors.his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
O’Donoghue et al. EJNMMI Research 2013, 3:42 Page 2 of 10
http://www.ejnmmires.com/content/3/1/42However, the optimal radiotracer has yet to be identified.
Typical candidate radiotracers for hypoxia imaging are
radiolabeled small molecules that freely diffuse into (and
out of) cells but are differentially metabolized in regions
of low pO2. In hypoxic cells, the molecules are irreversibly
reduced and their radiolabeled metabolites bind to macro-
molecules, resulting in intracellular trapping. Conversely,
in non-hypoxic cells, the molecules remain operationally
intact and diffuse back out again. Achieving a hypoxia im-
aging differential requires that the radiolabeled tracer ac-
cumulates in sufficient quantity in hypoxic regions while
clearing relatively quickly from normoxic regions.
However, hypoxia in tumors is, at least partly, a conse-
quence of a dysregulated and chaotic vascular network
leading to an imbalance between oxygen supply and
demand. It is likely that this dysfunctional vasculature
will also impose some restriction on the delivery of mo-
lecular tracers for hypoxia imaging. In contrast, the sup-
ply of such tracers to better-vascularized non-hypoxic
tumor regions is likely to be greater. Accordingly, the
intratumoral distribution of a hypoxia tracer would be
expected to undergo a kinetic evolution from an initial
state, where it is dominated by vascular supply (higher
tracer concentrations in non-hypoxic regions), toward a
final state, where it is dominated by the accumulation of
trapped metabolites (higher concentrations in hypoxic
regions). The hypoxia selectivity of such tracers would
thus be expected to increase with time.
There are, however, practical limits to the length of time
that is available between tracer administration and im-
aging. The most commonly used 2-nitroimidazole-based
hypoxia radiotracers (18F-fluoromisonidazole [12,13]
(18F-FMISO), 18F-fluoro-azomycin-arabinoside [14,15]
(18F-FAZA), 18F-2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,
3,3-pentafluoropropyl)-acetamide [16,17] (18F-EF5), 18F-
fluoro-erythronitroimidazole [18,19] (18F-FETNIM)) are
all labeled with the positron-emitting radionuclide
fluorine-18 (18F), and its relatively short (110 min) half-life
limits the time for PET image acquisition to a maximum
of approximately 3 h post-injection. This may be insuffi-
cient to produce a static image that reflects only tumor
hypoxia. In principle, the longer (12.6 h) half-life of 64Cu
allows later imaging times for the candidate hypoxia radio-
tracer 64copper-diacetyl-bis(N4)-methylthiosemicarbazone
(64Cu-ATSM). However, current clinical imaging studies
of 64Cu-ATSM typically involve early (<1 h post-injection)
imaging [20,21], partly due to historical experience with
positron-emitting isotopes of Cu with shorter half-lives
(e.g., 60Cu = 24 min, 62Cu = 10 min) [22,23].
As an alternative to static imaging, kinetic analysis of
dynamically acquired PET data has been proposed for
assessment of tumor hypoxia [24,25]. This enables
generation of parametric images of uptake rate constants
or time-activity curve slopes which may, due to thedeconvolution of ‘supply’ (i.e., vascular functionality) and
‘demand’ (i.e., hypoxic bioreduction), provide a more ac-
curate representation of tumor hypoxia. This approach,
however, has problems of its own related to the long and
complex imaging protocols required, image noise, and the
accurate determination of arterial input function.
Based on the foregoing considerations, we decided to
investigate the use of a long-lived radiolabeled 2-
nitroimidazole compound, 124I-iodoazomycin galacto-
pyranoside (124I-IAZGP) to enable late static imaging of
tumor hypoxia. The positron-emitting radionuclide 124I
has a half-life of 4.2 days enabling, in principle, imaging
at times in excess of 24 h post-injection. Additionally, a
series of in vitro studies with tumor cells in culture and
in vivo studies in murine xenograft models provided
support for the hypothesis that 124I-IAZGP might be a
superior radiotracer for non-invasive imaging of tumor
hypoxia using late PET imaging [26-28]. In order to
study 124I-IAZGP in human subjects, an investigational
new drug application (IND 72,013) was submitted to the
US Food and Drug Administration (FDA). Subsequently,
we performed a clinical study to evaluate the safety,
biodistribution, and imaging characteristics of 124I-
IAZGP in a group of patients with advanced colorectal
cancer and head and neck cancer using serial PET im-
aging. We now present the results of this clinical study.
Methods
Clinical study with 124I-IAZGP
Under the auspices of a protocol approved by the Insti-
tutional Review Board and an Investigational New Drug
application approved by the FDA, ten patients (eight
males, two females) with either colorectal or head and
neck cancer were intravenously administered 1 mg of
IAZGP labeled with 124I after having provided informed
consent (trial registration ID NCT00588276). Patients
underwent serial whole-torso (head/neck to pelvis) PET
imaging together with multiple whole-body counts and
blood draws. Potential thyroid uptake of 124I was blocked
by oral administration of potassium iodide (ten drops of
SSKI) initiated 2 days before and continued for 2 days
after administration of the radiotracer.
Radiotracer
A single lot of cold precursor stable iodoazomycin
galactopyranoside (IAZGP also known as 1-(6-deoxy-6-
iodo-β-D-galactopyranosyl)-2-nitroimidazole), synthesized
in accordance with cGMP principles by Dr. R.F. Schneider
as described previously [26], was used for all clinical
studies. IAZGP was radiolabeled with 124I produced on an
in-house cyclotron (TR19/9, EBCO Technologies, Inc.,
Vancouver, Canada) by exchange labeling and purified by
AgCl-treated celite/anion exchange chromatography as
described previously [26]. The radiolabeled drug product
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saline (pH 6 to 8). Specific activity was nominally 148
MBq/mg (4 mCi/mg) with a radiochemical purity >95%.
PET imaging
The initial plan was to perform serial whole-torso 124I-
IAZGP PET scans in a series of ten patients with each
patient administered 1 mg of IAZGP labeled with 148
MBq (4 mCi) of 124I. Following discussions with the
FDA, the first three patients were administered a re-
duced activity (nominally 111 MBq:3 mCi) of 124I, and a
provisional analysis was performed before further patient
accrual. The provisional analysis led us to modify the
imaging scheme for the remaining patients in the study.
Specifically, the first three patients were imaged on three
to four occasions at nominal times of 3, 18 to 24, and 48
h following injection of 111 MBq of 124I-IAZGP (im-
aging scheme A). The seven remaining patients were im-
aged on three occasions at nominal times of 3, 6 to 8,
and 24 h following injection of 148 MBq of 124I-IAZGP
(imaging scheme B). For the first three patients, at least
one scan was a PET/computer tomography (CT) scan
(GE Discovery LS, Waukesha, WI, USA) with the
remaining scans as PET only (GE Advance). For the sub-
sequent seven patients, all scans were PET/CT scans
(GE Discovery LS, n = 1; GE Discovery ST, n = 1; GE
Discovery STE, n = 5). Torso (head/neck to pelvis) PET
scans, typically comprising 6 to 7 bed positions, were ac-
quired in two-dimensional (2D) mode with attenuation,
scatter, and other standard corrections applied to yield
quantitative (Bq/ml) PET images. 124I-IAZGP PET scans
were interpreted by a board-certified nuclear medicine
physician with lesions, identified from contemporaneous
18F-fluorodeoxyglucose (FDG) PET scans, scored as ei-
ther positive or negative for 124I-IAZGP uptake.
Absorbed dose estimates for 124I-IAZGP
Absorbed doses to normal tissues for 124I-IAZGP were
estimated using measured whole-body and blood clear-
ance data, together with uptake data derived from
region-of-interest (ROI) analysis of the serial PET scans.
Dose estimates were generated using organ-level internal
dose assessment/exponential modeling (OLINDA/EXM)
[29] for either standard ‘Adult Male’ or ‘Adult Female’
model as appropriate. The input data consisted of cumu-
lative activity per unit administered activity (also known
as residence time) for 124I-IAZGP for a set of source or-
gans, as discussed in detail below.
Whole-body and blood clearance
Whole-body clearance was determined by serial mea-
surements of count rate by a NaI(Tl) scintillation probe.
Duplicate anterior and posterior measurements were
made at fixed geometry, and background-correctedgeometric mean values were used for clearance curve fit-
ting. Probe measurements were made immediately post-
administration before first voiding, after each voiding
over a period of approximately 3 h post-administration,
and subsequently at the times of PET imaging. The me-
dian number of whole-body count rate measurements
was 7 (range, 5 to 10). Count rates were normalized to
the value immediately post-administration (taken as
100%) to yield relative retained activities (%).
A median of 10 (range, 9 to 10) venous blood samples
(approximately 5 ml) were drawn at nominal times of 5,
15, 30, and 60 min after administration of 124I-IAZGP,
and before and after each scan up to the nominal 24-h
time point. Aliquots (500 μl) of blood or serum were
counted in duplicate in a NaI(Tl) gamma well-type de-
tector (Wallac Wizard 1480 automatic gamma counter,
PerkinElmer, Waltham, MA, USA) calibrated for 124I,
the net count rates converted to activities and the results
expressed in terms of percentage of the injected dose
per unit volume (%ID/l). It was verified, using multiple
patient samples, that whole blood and serum activity
concentrations were equivalent.
Bi-exponential functions were fitted to the whole-body
and blood clearance data using the software application
SAAM II (University of Washington, Seattle, WA, USA).
Parenchymal organs (liver, kidneys, spleen, lung, and
thyroid)
Multiple ROIs were drawn on several transverse CT
slices for each of the liver, kidneys, spleen, lung, and thy-
roid and copy/pasted onto the corresponding PET slices.
The average activity concentrations in each ROI (Bq/ml)
were recorded, and the overall average values were de-
rived for each organ. The total activity in each organ
was estimated by multiplying the activity concentration
by standard male or female organ masses (i.e., the
masses used in OLINDA/EXM). The density of all or-
gans was assumed to be 1 g/ml, except for the lung
which was assumed to be 0.3 g/ml. Total cumulated ac-
tivities in the organs were estimated by trapezoidal inte-
gration of the activity-time curve and expressed as
cumulative activity per unit administered activity (h) for
input into OLINDA/EXM.
Gastrointestinal tract
The fraction of activity clearing via the gut was esti-
mated from the PET scans acquired the day after admin-
istration of 124I-IAZGP. It was assumed that all activity
clearing via this route would be present in the gut at this
time, based on respective nominal transit times of 4, 13,
and 24 h for the small, upper large, and lower large in-
testines [30]. PET images were reformatted to generate
summed coronal and sagittal projections, and ROIs were
drawn to encompass the entire visible intestine; ROI
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counts in the patient. The fraction of administered 124I-
IAZGP present in the intestine was estimated by multi-
plying the average of the coronal and sagittal count
fractions by the decay-corrected whole-body activity at
the time of scanning (derived from the whole-body
clearance curve). This was then used as input to the
ICRP 30 gastrointestinal (GI) module of OLINDA/EXM
to yield cumulative activity per unit administered activity
for the small, upper large, and lower large intestines.
Cardiac contents and red marrow
Estimates of cumulative activity per unit administered
activity for cardiac contents and the red marrow were
derived from the blood clearance curve. The volume of
the cardiac contents was taken as 510 ml for males and
370 ml for females, based on standard values [31]. Red
marrow mass was taken as 1,120 g for males and 1,300 g
for females, corresponding to the values used in
OLINDA/EXM. Given the equivalent activity concentra-
tions between whole blood and serum and the implica-
tion of unhindered trans-plasma membrane transport of
124I-IAZGP, the conservative assumption was made that
the activity concentration in the red marrow was equal
to that in the whole blood.
Urinary bladder
It was assumed that any material not cleared via the GI
tract was cleared via the urinary bladder. As this
corresponded to the majority of administered 124I-
IAZGP, the conservative assumption was made that the
pharmacokinetics of urinary clearance was identical to
the bi-exponential whole-body clearance, and these pa-
rameters (fractions and biological half-times) were used
in the voiding bladder model of OLINDA/EXM.Table 1 Patient characteristics








2 Tonsil Squamous Moderate to poor cT
3 Tonsil Squamous Poor cT




6 Rectum Adenocarcinoma Moderate pT
7 Rectum Adenocarcinoma Moderate pT
8 Rectum Adenocarcinoma Moderate cT
9 Supraglottic larynx Squamous Moderate cT
10 Sigmoid Adenocarcinoma Moderate cT
Serial whole-body, blood, and PET data were acquired for patients 1 to 10. Post-ima
chemoradiotherapy, NED no evidence of disease. Imaging schemes: A = 3, 18 to 24
124I-IAZGP injection.Results and discussion
Results
PET imaging with 124I-IAZGP
Ten patients completed the study, including five pa-
tients with colorectal cancer, four patients with head
and neck cancer, and one patient with pseudomyxoma
peritonei (Table 1). No adverse effects related to the
administration of 124I-IAZGP were observed in any pa-
tient. 18F-FDG PET scans acquired shortly before 124I-
IAZGP administration indicated FDG-avid disease in all
patients. However, all 124I-IAZGP PET scans were
interpreted as negative, i.e., there was no differential or
focal uptake of 124I-IAZGP in any disease site at any
time. Figure 1 shows an example of a patient with FDG-
avid primary rectal cancer with widespread FDG-avid
liver metastases, indicating the absence of 124I-IAZGP
uptake in any sites of disease. Figure 2 shows a patient
with head and neck cancer where, again, 124I-IAZGP
uptake is not observed in FDG-avid disease. Addition-
ally, as illustrated in both figures, there was no focal
124I-IAZGP uptake in any parenchymal organ in any pa-
tient at any time. Physiologic/excreted 124I was seen in
the urinary and GI tracts and the salivary glands.
Biokinetics of 124I-IAZGP
Clearance of 124I-IAZGP from the whole body and blood
was very rapid and was adequately described by bi-
exponential clearance curves of the form A(t) = A1 exp
(−a1t) + A2 exp(−a2t). The best-fit parameters for the
whole body indicated that, on average, two thirds of the
activity cleared with an effective half-time of 1 h and the
remaining one third with an effective half-time of 11 h
(Table 2). For blood, the average effective T1/2 values for
the faster and slower clearance components were 0.24










N/A 116 A (−) None N/A
1N2M0 108 A (−) Radiation NED
4N2M0 59 A (−) CRT NED
1N1M0 160 B (−) CRT NED
4N2M0 148 B (−) CRT 95%
3N0M1 141 B (−) Chemotherapy 50%
3N0M0 150 B (−) CRT 60%
4NxM1 159 B (−) Chemotherapy Progression
3N2M0 157 B (−) CRT NED
xN2M1 159 B (−) Chemotherapy Progression
ging clinical management and response are also shown. CRT
, and 48 h post 124I-IAZGP injection; B = 3, 6 to 8, and 24 h post
Figure 1 PET/CT images of 18F-FDG and 124I-IAZGP in a rectal cancer patient. (A to D) Coronal maximum intensity projection PET images of
18F-FDG acquired 3 days before 124I-IAZGP administration (A) and 124I-IAZGP acquired at 3 h (B), 6 h (C), and 25 h (D) post-administration in a
patient with primary rectal cancer with liver metastases. (E to G) Cross-sectional fused PET/CT images of the same patient comparing 18F-FDG
(E and F left, G top) with 124I-IAZGP at 3 h (E and F right, G bottom). No evidence of 124I-IAZGP uptake is seen in either FDG-avid primary or
metastatic lesions. The 124I-IAZGP MIP images (B to D) also illustrate the characteristic pattern of 124I-IAZGP clearance, initially via the urinary tract
with longer term excretion via the GI tract. Note that image intensities are not directly comparable as window levels were adjusted to maximize
feature visibility.
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and, to a lesser extent, renal components visible at early
imaging times. At later times (approximately 24 h post-
administration), a significant proportion (up to 50%) of
total activity was visible in the intestines. However, by
this time, the amount of activity present in the whole
body was only a small fraction (<10%) of that adminis-
tered. The fraction of 124I-IAZGP clearing via the intes-
tinal route was estimated to be, on average, 0.03 (range,
0.02 to 0.05) of that administered (Table 2).Residence times and absorbed dose estimates for normal
tissues
Table 3 shows the values of cumulated activity per unit
administered activity (i.e., residence time) estimated for
patients 1 to 10 as described in the ‘Methods’ section.
The OLINDA/EXM-derived absorbed dose estimates
based on these input data, together with the associated
effective dose [32] values, are shown in Table 4. This in-
dicates that the tissues receiving the highest absorbed
doses were the mucosal walls of the urinary bladder and
Figure 2 PET/CT images of 18F-FDG and 124I-IAZGP in a head and neck cancer patient. (A to D) Coronal maximum intensity projection PET
images of 18F-FDG acquired 3 days before 124I-IAZGP administration (A) and 124I-IAZGP acquired at 3 h (B), 6 h (C), and 27 h (D) post-
administration in a patient with head and neck cancer. (E to G) Cross-sectional fused PET/CT images of the same patient comparing 18 F-FDG
(E and F left, G top) with 124I-IAZGP at 6 h (E and F right, G bottom). No evidence of 124I-IAZGP uptake is seen in either the FDG-avid supraglottic
larynx cancer or the approximately 2-cm lymph node. The clearance of 124I-IAZGP is similar to that seen in Figure 1, with a symmetric distribution
of physiologic 124I in the salivary glands. Note that image intensities are not directly comparable and that the 18F-FDG image was acquired in the
radiotherapy treatment position with the patient in a facial mask.
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Average estimated absorbed doses to the bladder wall
(0.27 to 0.69 mGy/MBq:1.0 to 2.5 cGy/mCi) were
dependent on the assumed frequency of voiding. The
average absorbed dose to the LLI wall was 0.35 mGy/
MBq (1.3 cGy/mCi). The highest average absorbed dose
estimate to the parenchymal organ was 0.056 mGy/MBq
(0.21 cGy/mCi) to the kidney followed by 0.044 mGy/
MBq (0.16 cGy/mCi) to the liver. The average absorbed
dose estimate to the thyroid was 0.022 mGy/MBq (0.082
cGy/mCi). For an administration of the clinically envis-
aged activity of 148 MBq (4 mCi) of 124I-IAZGP, the
average absorbed dose to the parenchymal organs wasestimated at 0.47 cGy with the kidney receiving an aver-
age absorbed dose of 0.83 cGy.
Discussion
This study was designed to evaluate the safety, bio-
distribution, and imaging characteristics of 124I-IAZGP
in human patients. In particular, the primary imaging
function was to assess the time-dependent biodistribution
of 124I-IAZGP throughout the whole body, rather than its
intratumoral distribution, and image acquisition parame-
ters were, necessarily, suboptimal for this latter role. It is
also important to note that, like other tumor hypoxia PET
tracers, 124I-IAZGP is not a tumor imaging agent per se,
Table 2 Kinetic clearance parameters for patients
Patient # 1 2 3 4 5 6 7 8 9 10 Mean SD
WB A1 0.67 0.89 0.86 0.70 0.80 0.50 0.67 0.28 0.71 0.67 0.67 0.18
WB a1 (h
−1) 0.29 0.24 0.38 1.11 0.45 2.10 0.53 0.89 0.52 0.98 0.75 0.56
WB A2 0.33 0.11 0.14 0.30 0.20 0.50 0.33 0.72 0.29 0.33 0.33 0.18
WB a2 (h
−1) 0.06 0.02 0.03 0.06 0.05 0.09 0.08 0.08 0.06 0.10 0.06 0.03
Blood A1 (%/l) 5.9 18.7 5.7 2.2 5.1 7.1 3.5 2.5 3.2 2.6 5.7 4.9
Blood a1 (h
−1) 5.1 6.5 5.8 0.8 1.3 5.6 0.7 1.4 0.8 1.0 2.9 2.5
Blood A2 (%/l) 1.3 2.48 1.2 0.38 0.68 0.88 0.88 1.07 0.74 0.61 1.01 0.58
Blood a2 (h
−1) 0.12 0.12 0.13 0.08 0.07 0.45 0.07 0.10 0.09 0.12 0.13 0.11
Gut fraction 0.031 0.030 0.027 0.049 0.037 0.033 0.030 0.050 0.047 0.016 0.03 0.02
Whole-body and blood clearance data were fitted to bi-exponential functions viz A(t) = A1 exp(−a1t) + A2 exp(−a2t), where t is time in hour. Gut fraction is the
estimated fraction of 124I-IAZGP present in the intestine at (nominally) 24 h after administration.
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tumors that had been pre-identified by other means.
Nevertheless, the fact that no differential uptake of 124I-
IAZGP was observed in any disease site must be consid-
ered disappointing. It is unlikely that this finding is due
to the absence of tumor hypoxia in the study patients.
For example, Figure 1 shows large volume FDG-avid,
centrally cold liver metastases suggestive of significant
central necrosis and thus likely to contain perinecrotic
hypoxic regions.
There is a major discrepancy between the previous
pre-clinical studies of 124I-IAZGP, which demonstrated
its ability to detect hypoxia in tumor cells both in vitro
and in small animal models [27,28,33,34], and these clin-
ical findings. One factor in this discrepancy may be re-
lated to the dilution effect when transitioning from aTable 3 Cumulated activity per unit administered activity (res
Patient nu
1 2 3 4 5
Sex M M M M M
Heart contents 0.061 0.117 0.050 0.037 0.071
Kidneys 0.112 0.161 0.108 0.035 0.035
Liver 0.24 0.55 0.53 0.19 0.17
Lungs 0.068 0.148 0.089 0.058 0.052
Red marrow 0.13 0.26 0.11 0.08 0.16
Spleen 0.014 0.034 0.039 0.013 0.011
Thyroid 0.0011 0.0039 0.0012 0.0009 0.001
LLI 0.56 0.54 0.49 0.90 0.62
SI 0.12 0.12 0.10 0.19 0.13
ULI 0.35 0.34 0.31 0.57 0.39
UB cont (1 h) 0.49 0.49 0.50 0.54 0.51
UB cont (2.5 h) 1.28 1.28 1.35 1.56 1.37
ROB (1 h) 6.35 6.20 4.84 3.49 4.41
ROB (2.5 h) 5.55 5.41 3.99 2.47 3.55
LLI lower large intestine, SI small intestine, ULI upper large intestine, UB cont (t), uri
a bladder voiding interval of t.small animal to a human subject (in terms of both mg/
kg and MBq/kg). Our pre-clinical studies used activities
of approximately 16.7 MBq in 25-g mice [27] or approxi-
mately 18.5 MBq in 200-g rats [28], corresponding to
approximately 100 to 700 MBq/kg. In contrast, patients
in this study were injected with approximately 148 MBq
corresponding to approximately 2 MBq/kg, a factor of
50 to 350 times less than the pre-clinical studies.
We hypothesized that the concentration of radioactiv-
ity in tumors might just be too low to be detected with
the clinical PET scan parameters used. In order to
address this, after the ten-patient imaging study was
complete, we included one additional patient who was
pre-scheduled for surgical resection of a sigmoid tumor.
For this patient, approximately 300 MBq (8 mCi) 124I-
IAZGP was administered the day before surgery, clinicalidence time) in hours for patients 1 to 10
mber Mean SD
6 7 8 9 10
M M M F F
0.017 0.089 0.063 0.046 0.029 0.058 0.030
0.065 0.043 0.048 0.055 0.037 0.070 0.043
0.13 0.24 0.31 0.17 0.14 0.27 0.15
0.046 0.074 0.106 0.062 0.046 0.075 0.032
0.04 0.19 0.14 0.16 0.10 0.14 0.06
0.011 0.012 0.013 0.011 0.008 0.017 0.011
0.001 0.002 0.001 0.001 0.001 0.0014 0.001
0.60 0.25 0.93 0.86 0.19 0.59 0.25
0.13 0.05 0.20 0.18 0.04 0.13 0.05
0.38 0.16 0.58 0.54 0.12 0.37 0.16
0.56 0.51 0.49 0.51 0.54 0.51 0.03
1.60 1.39 1.31 1.38 1.53 1.41 0.12
4.14 4.16 6.40 4.21 3.14 4.73 1.19
3.10 3.28 5.58 3.34 2.15 3.84 1.26
nary bladder contents for a voiding interval of t; ROB (t), remainder of body for
Table 4 Estimated absorbed dose to normal tissues for 124I-IAZGP
Patient number Mean SD
1 2 3 4 5 6 7 8 9 10
Sex M M M M M M M M F F
Adrenals 0.038 0.043 0.034 0.022 0.027 0.024 0.021 0.039 0.034 0.022 0.030 0.008
Brain 0.025 0.025 0.019 0.013 0.017 0.016 0.015 0.026 0.021 0.015 0.019 0.005
Breasts 0.024 0.025 0.020 0.013 0.017 0.015 0.015 0.025 0.021 0.014 0.019 0.005
Gallbladder wall 0.046 0.053 0.045 0.035 0.036 0.033 0.026 0.054 0.047 0.026 0.040 0.011
LLI wall 0.33 0.32 0.29 0.49 0.35 0.34 0.16 0.52 0.52 0.14 0.35 0.13
Small intestine 0.080 0.080 0.068 0.090 0.074 0.071 0.043 0.108 0.110 0.042 0.077 0.023
Stomach wall 0.039 0.041 0.033 0.027 0.029 0.027 0.023 0.043 0.038 0.022 0.032 0.008
ULI wall 0.16 0.16 0.14 0.23 0.17 0.16 0.08 0.25 0.25 0.07 0.17 0.06
Heart wall 0.043 0.057 0.036 0.024 0.036 0.022 0.020 0.045 0.037 0.025 0.035 0.012
Kidneys 0.083 0.112 0.079 0.036 0.037 0.051 0.021 0.053 0.055 0.035 0.056 0.028
Liver 0.044 0.081 0.074 0.034 0.033 0.027 0.021 0.055 0.043 0.030 0.044 0.020
Lungs 0.028 0.042 0.029 0.019 0.021 0.018 0.018 0.035 0.027 0.019 0.025 0.008
Muscle 0.035 0.035 0.029 0.024 0.027 0.025 0.022 0.038 0.033 0.022 0.029 0.006
Pancreas 0.040 0.044 0.035 0.024 0.029 0.026 0.023 0.043 0.036 0.023 0.032 0.008
Red marrow 0.041 0.049 0.034 0.029 0.035 0.026 0.020 0.046 0.042 0.025 0.035 0.010
Osteogenic cells 0.049 0.053 0.039 0.029 0.037 0.030 0.027 0.052 0.048 0.031 0.039 0.010
Skin 0.024 0.025 0.020 0.015 0.018 0.016 0.015 0.026 0.022 0.015 0.019 0.004
Spleen 0.035 0.055 0.053 0.026 0.025 0.025 0.020 0.035 0.032 0.022 0.033 0.012
Testes 0.039 0.039 0.033 0.029 0.031 0.031 0.027 0.042 - - 0.034 0.005
Thymus 0.030 0.033 0.024 0.016 0.022 0.018 0.018 0.032 0.026 0.018 0.024 0.006
Thyroid 0.025 0.044 0.022 0.016 0.019 0.016 0.018 0.027 0.021 0.014 0.022 0.009
Total body 0.037 0.039 0.031 0.026 0.028 0.026 0.022 0.041 0.036 0.023 0.031 0.007
UB wall (1 h) 0.25 0.25 0.25 0.26 0.25 0.27 0.24 0.26 0.35 0.35 0.27 0.04
UB wall (2.5 h) 0.58 0.58 0.61 0.69 0.61 0.71 0.61 0.61 0.88 0.95 0.68 0.13
Effective dose (mSv/MBq) 0.097 0.10 0.089 0.11 0.094 0.093 0.061 0.13 0.13 0.072 0.098 0.023
All absorbed dose values are expressed in mGy/MBq. Effective dose is expressed in mSv/MBq [32]. Urinary bladder (UB) wall (t) denotes absorbed dose to the
bladder wall for a voiding interval of t.
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administration, and following surgery, the entire surgi-
cal specimen was imaged on a microPET scanner. In
addition, tumor tissue sections cut from the surgical
specimen were exposed to a phosphor imaging plate for
up to 7 days for digital autoradiography (DAR). How-
ever, not only were the clinical PET scans negative as
before, but the ex vivo evaluation of the surgical speci-
men also returned negative results. (Additional file 1:
Figure S1 shows the DAR results).
The biodistribution of 124I-IAZGP was characterized
by rapid clearance from the blood and whole body pri-
marily via the urinary and, to a lesser extent, GI tracts,
with no significant uptake in the parenchymal tissues
apart from the salivary glands, presumably reflecting
dissociated iodine. In terms of radiation exposure, 148
MBq (4 mCi) of 124I-IAZGP produced absorbed doses to
normal parenchymal tissues less than or equal to thoseproduced by typical clinical activities (370 to 444 MBq;
10 to 12 mCi) of 18F-FDG. However, the absorbed doses
to the large intestinal and urinary bladder walls were
significantly greater for 124I-IAZGP than 18F-FDG. As
absorbed doses to the urinary bladder wall depend on the
frequency of voiding, study patients were encouraged to
hydrate and to void frequently in order to minimize this.
There is no doubt that the use of long-lived positron-
emitting nuclides for imaging has intrinsic dosimetric
disadvantages compared to short-lived radionuclides,
where the balance between image quality and patient
dose is usually more favorable. However, the use of a
long half-life radionuclide is unavoidable if it takes a
long time for sufficient biological contrast to develop;
our hypothesis was that PET imaging of tumor hypoxia
was such a case. An additional disadvantage associated
with 124I is its relatively low positron yield (approximately
24%) coupled with the presence of multiple high-energy
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tio of PET image quality to patient radiation dose.
We found that PET imaging of 124I-IAZGP in 2D
mode was possible up to, at least, 6 to 8 h post-
administration and possibly 24 h, although with an en-
hanced likelihood of low-count reconstruction artifacts.
However, imaging at 48 h was generally not feasible with
the activities (approximately 148 MBq) and emission
times (typically 6 to 8 min per bed position) used in this
study. This contrasts to the case where 124I is used to
label antibodies with prolonged biological retention, for
which clinically useful images may be acquired at times
of up to 1 week post-administration [35,36]. This defi-
ciency may be alleviated to some extent by the use of
3D reconstruction methods as long as appropriate cor-
rections are included for cascade coincidences.
However, even with foreseeable improvements in image
acquisition and reconstruction methods, our data indicate
the uptake of 124I-IAZGP in tumors is insufficient to sug-
gest any clinical role in the management of patients with
colorectal or head and neck cancer.
Conclusions
The study reported here is the first trial describing the
toxicity and biodistribution of 124I-IAZGP in human
subjects. We found that the administration of 124I-
IAZGP was safe and that it was rapidly cleared from the
body. PET imaging failed to show any differential uptake
of 124I-IAZGP in any disease site. While we continue to
believe that characterization of tumor hypoxia will be
important for individualizing patient treatments, 124I-
IAZGP PET in its current form is unlikely to provide
any clinical utility for assessing hypoxia in colorectal
cancer and head and neck cancer. Despite these negative
results with 124I-IAZGP, there is still a strong theoretical
rationale for the concept that late PET imaging should
provide the most specific indication of tumor hypoxia. It
is hoped that new hypoxia agents will emerge, perhaps
featuring alternative long-lived positron-emitting radio-
nuclides such as 64Cu, 89Zr, or 76Br, which can provide a
convenient way to perform single time-point imaging of
tumor hypoxia.
Additional file
Additional file 1: Figure S1. Representative frozen sections from
patient surgical specimen showing (left) H&E, (center) digital
autoradiogram without digital manipulation, i.e., each section is
quantitatively comparable, and (right) digital autoradiogram optimized to
maximize contrast. The exposure time for the autoradiograms was 4 days.
Overall, the absolute amount of 124I in the tumor is low (compare signal/
background in center) and relatively uniform with no enhancement in
tumor uptake compared to normal colon.
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